Clinical Trials Browser

AP 1903 reagent × Lymphoid × 1 year × Clear all

NCT07164469 2026-06-05

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Phase 2 Not yet recruiting

100 enrolled

Lymphoid

Hodgkin Disease

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1 Active not recruiting

19 enrolled

Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

17 enrolled

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01494103 2025-07-11

DOTTI

Phase 1 Active not recruiting

15 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma